OncLive Peer Exchange Provides Perspective on How the Latest Research from the World Conference for Lung Cancer and the ESMO Annual Meetings Translate to Patient Care and Clinical Practice

OncLive Peer Exchange Provides Perspective on How the Latest Research from the World Conference for Lung Cancer and the ESMO Annual Meetings Translate to Patient Care and Clinical Practice

Suresh S. Ramalingam, MD, FASCO, Winship Canter Institute of Emery University, leads the discussion on the impact of overall survival data from the FLAURA trial treating advanced non-small cell lung cancer (NSCLC). Panelists include Byoung Chul Cho, MD, PhD, Yonsei...
Therapy Advancements and Biomarker Identifications Leading to Improved Ability to Predict and Enhance Responses To Immunotherapeutic Agents In Non–Small Cell Lung Cancer (NSCLC)

Therapy Advancements and Biomarker Identifications Leading to Improved Ability to Predict and Enhance Responses To Immunotherapeutic Agents In Non–Small Cell Lung Cancer (NSCLC)

Targeted therapy advancements and the identification of emerging biomarkers of response to treatment have led to an improved ability to predict and enhance responses to immunotherapeutic agents in non–small cell lung cancer (NSCLC). Available agents that have...

Pin It on Pinterest